Both raise your own growth hormone, but sermorelin is the more conservative choice: it is a GHRH analog once FDA-approved as Geref, now compounded. MK-677 is a never-approved oral pill; in a 2-year trial it added 1.1 kg of lean mass but no strength, raised blood sugar, and a hip-fracture trial stopped early over heart failure. Neither has proven anti-aging benefit.
MK-677 and sermorelin are the two most-asked-about ways to raise growth hormone without injecting GH itself. They aim at the same axis but enter it through different doors, and the practical differences — oral vs injected, approved vs not, and their safety profiles — are what should actually decide between them. For each on its own, see the MK-677 monograph and the sermorelin monograph.
Same axis, two entry points
Both are growth hormone secretagogues — they prompt your own pituitary to release more GH rather than supplying GH from outside. But they push different levers. MK-677 is an oral ghrelin mimetic: it acts on the ghrelin pathway to amplify pulsatile GH release and sustain elevated IGF-1.[1] Sermorelin is a GHRH(1-29) analog — the active fragment of growth-hormone-releasing hormone — that stimulates the pituitary’s GHRH receptor, producing a more physiologic GH pulse.[3] Same destination, different on-ramp.
| MK-677 (ibutamoren) | Sermorelin | |
|---|---|---|
| What it is | Oral non-peptide ghrelin mimetic | Injectable GHRH(1-29) peptide analog |
| Route | Oral, once daily | Subcutaneous injection |
| Pathway | Ghrelin receptor | GHRH receptor (pituitary) |
| GH pattern | Long-acting, sustained IGF-1 | Shorter-acting, more pulsatile |
| Approval | Never approved — research chemical | Was FDA-approved (Geref, 1990); brand discontinued, now mostly compounded |
| FDA compounding list (Oct 2026) | Category 2 (safety risk) for 503A and 503B | Not on the Category 2 list |
| Sport (WADA) | Prohibited (GH secretagogue) | Prohibited (GHRH analog) |
| Key safety flags | ↑ glucose; a cardiac signal | More physiologic; fewer metabolic flags |
Oral vs injectable, long vs short
The most obvious practical difference is convenience. MK-677 is a once-daily pill; sermorelin is a subcutaneous injection, typically at night. But the route ties to a deeper difference in how each shapes GH. MK-677’s long action keeps IGF-1 elevated continuously, which is potent but less like the body’s natural rhythm; sermorelin’s shorter action produces a GH pulse closer to physiologic — one reason it’s often framed as the “gentler” option. Whether continuous elevation or pulsatile mimicry is better for any given goal is, honestly, not settled by outcome trials for either drug.
The approval difference
This is the cleanest distinction. Sermorelin is a real, approved drug with a genuine clinical pedigree. In children with idiopathic growth-hormone deficiency, a nightly 30 µg/kg injection produced sustained gains in height velocity over 12 months, though smaller than somatropin’s.[3] It was FDA-approved as Geref (first in December 1990); both Geref applications are now listed as discontinued, and sermorelin is supplied largely through compounding pharmacies.[4] MK-677 was never approved for anything; despite a deep trial record, it remained investigational and is sold mostly as a research chemical. The FDA lists ibutamoren in Category 2, substances that may pose significant safety risks in compounding, for both 503A pharmacies and 503B outsourcing facilities; sermorelin is not on that list.[5] So sermorelin at least has a regulated history and a manufactured precedent; MK-677 does not. That approval gap widens further against recombinant growth hormone itself: as the oral-secretagogue-versus-injected-HGH comparison sets out, one is an approved medicine and the other a never-approved research chemical — and neither has proven an anti-aging benefit.
The safety difference
What neither has proven
The honest equalizer: neither drug has shown the anti-aging, strength, or longevity outcomes they’re marketed for. In a two-year randomized trial in 65 healthy older adults, MK-677 moved fat-free mass +1.1 kg against −0.5 kg on placebo (P < 0.001) — and the authors record flatly that the increased fat-free mass did not result in changes in strength or function, while fasting glucose rose 0.3 mmol/L (P = 0.015).[1] Its hip-fracture outcome trial raised IGF-1 by 51.4 ng/mL but improved gait speed and not most other function measures (stair-climbing power p = 0.292), and was halted early on a heart-failure signal, with the authors concluding an “unfavorable safety profile” in that population.[2] Sermorelin’s evidence for healthy-adult benefit is similarly built more on biomarkers than on hard outcomes. Both reliably move the GH-IGF-1 axis; neither has shown that doing so makes a healthy adult measurably better off.
The honest bottom line
If you frame it as a choice: sermorelin is the more conservative pick — an actual approved GHRH analog with a more physiologic action and fewer documented safety flags, now mostly compounded. MK-677 is more convenient (oral, once daily) and a more potent, sustained IGF-1 raiser — but it was never approved and carries the clearer metabolic and cardiac risks.[2][3] Crucially, there is no head-to-head trial and no proven outcome benefit for either in healthy adults, so this is a comparison of profiles, not of demonstrated results. For the deeper dives, see the MK-677 side effects and sermorelin evidence pages.
